Latest Advaxis Stories
NEW YORK, Jan.
NEW YORK, Jan. 22, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS).
KANSAS CITY, Kan., July 2, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused
Inovio Responds to False and Misleading Speculation Regarding Immunotherapy Study BLUE BELL, Pa., June 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
PRINCETON, N.J., May 29, 2014 /PRNewswire/ -- inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis,
Grant Earmarked for Trial Drug Aimed at Treatment of Anal Cancer LOS ANGELES, April 30, 2014 /PRNewswire/ -- The Farrah Fawcett Foundation (FFF) has presented a $50,000 grant
LONDON, April 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
-- Collaboration Focused on Cancer Immunotherapies for Pets -- KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Advaxis, Inc. NEW YORK, Feb.